Lyme Opportunity Valneva’s Lyme disease vaccine candidate with Pfizer, including EMA validation of the MAA and expected regulatory progress, represents a high-margin, royalty-focused growth path. This signals potential upsell opportunities with regional healthcare distributors and hospital networks once regulatory milestones translate into commercial launches.

Royalty Transition The shift toward a high-margin royalty and milestone model, anchored by Lyme collaboration, implies sustained recurring revenue potential. BD teams can position services around licensing negotiations, milestone capture strategies, and partnerships that optimize royalty outcomes for stakeholders and investors.

Public Health Demand Valneva’s focus on vaccines addressing unmet medical needs and threats like Zika and Lyme positions it to engage with government programs, global health agencies, and procurement bodies seeking strategic vaccine portfolios for pandemic preparedness and vector-borne diseases.

Geographic Reach With operations across Europe, North America, and Canada, there are multiple regional markets and regulatory landscapes to target for distribution partnerships, co-marketing arrangements, and local manufacturing or technology transfer deals to accelerate scale.

Financial Readiness Recent restructuring improving cash runway and a solid cash position, coupled with a funded pipeline, creates an opening to pursue strategic collaborations, manufacturing partnerships, and co-development deals that align with Valneva’s capital-friendly stance.